Dr. Reddy's Laboratories
RDYApprovedDr. Reddy's Laboratories is a vertically integrated pharmaceutical company with capabilities spanning drug discovery, development, manufacturing, and commercialization. The company has built a strong portfolio of generic drugs, particularly in the US market, while also investing in complex generics, biosimilars, and proprietary drug development. With manufacturing facilities across multiple countries and a global workforce, Dr. Reddy's continues to expand its market presence through strategic partnerships, acquisitions, and new product launches. The company is publicly traded on both Indian stock exchanges and NASDAQ, reflecting its status as a major player in the global pharmaceutical industry.
RDY · Stock Price
Historical price data
AI Company Overview
Dr. Reddy's Laboratories is a vertically integrated pharmaceutical company with capabilities spanning drug discovery, development, manufacturing, and commercialization. The company has built a strong portfolio of generic drugs, particularly in the US market, while also investing in complex generics, biosimilars, and proprietary drug development. With manufacturing facilities across multiple countries and a global workforce, Dr. Reddy's continues to expand its market presence through strategic partnerships, acquisitions, and new product launches. The company is publicly traded on both Indian stock exchanges and NASDAQ, reflecting its status as a major player in the global pharmaceutical industry.
Technology Platform
Integrated pharmaceutical company with capabilities in generic drug development, biosimilars, active pharmaceutical ingredients (APIs), and complex generics manufacturing with global regulatory expertise.
Pipeline Snapshot
236236 drugs in pipeline, 18 in Phase 3
| Drug | Indication | Stage |
|---|---|---|
| NISE | Knee Osteoarthritis | Approved |
| Levofloxacin + Levofloxacin | Urinary Tract Infection | Approved |
| Ketorolac Tromethamine + Ketoprofen | Gonarthrosis | Approved |
| OMEZ 40 + OMEZ 80 | GERD | Approved |
| omeprazole+domperidone SR + omeprazole | GERD | Approved |
Funding History
1Total raised: $100M
FDA Approved Drugs
44Opportunities
Risk Factors
Competitive Landscape
Dr. Reddy's competes with major generics players like Teva, Sandoz, and Sun Pharma while differentiating through complex generics expertise and biosimilar capabilities. The company maintains competitive advantages through its integrated business model, regulatory expertise, and diversified geographic presence.
Company Info
Trading
Contact
Therapeutic Areas
Partners
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile